BioSpace News Archive

Kriya Therapeutics, Inc. (“Kriya”) has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ suprachoroidal delivery device.

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced that the University of North Carolina Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense to investigate the potential of Tonix’s TNX-102 SL to reduce the frequency and severity of adverse effects of acute trauma.

Microbot Medical Inc. announced its partnership with a Contract Research Organization in the U.S. This is an additional step in the preparations to the commencement of the Company’s planned upcoming clinical trial.

Apex Labs Ltd. (APEX or the Company) is excited to announce that a physician has been authorized to receive APEX-90 macrodose psilocybin drug product via Health Canada’s Special Access Program (SAP) for the treatment of a Canadian Armed Forces Veteran suffering from Treatment Resistant Depression (TRD).

Everads Therapy announced today that it has entered into a license, collaboration and supply agreement with Kriya Therapeutics, Inc. (“Kriya”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ suprachoroidal delivery platform.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) today announced that an abstract highlighting pre-clinical data on its CRB-601 anti-aVb8 integrin monoclonal antibody has been accepted for presentation as a poster at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), to be in San Diego, CA November 1-5, 2023.

Bio-Techne Corporation was pleased to host presentations by three industry experts yesterday at the CASSS CE Pharm conference in Philadelphia, PA. These industry experts highlighted how Bio-Techne’s ProteinSimple branded Maurice™ and MauriceFlex™ systems improved their therapeutic development workflows.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that results from a double-blind, randomized, placebo-controlled Phase 2 etripamil study will be presented at the American Heart Association (AHA) Scientific Sessions 2023.

Can-Fite BioPharma Ltd today announced that its study titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via De-regulation of the Wnt/β-catenin Signaling Pathway” has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer, held from September 27-30, 2023, in Boston, Massachusetts.

Deep Genomics announced today the release of the manuscript, “An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics” introducing the company’s AI foundation model, BigRNA.